Abstract | BACKGROUND: METHODS: Eligible patients were randomized to receive one of three masked doses of gabapentin (300, 900, or 1,800 mg/day) or open-label carbamazepine (600 mg/day) and kept daily seizure diaries throughout the study. After titration, patients entered a 24-week evaluation phase. Patients were required to exit the study if they experienced an exit event, defined as a total of three simple or complex partial seizures, one generalized tonic-clonic (GTC) seizure, or status epilepticus. Patients could be withdrawn for lack of efficacy, adverse events, or noncompliance. Kaplan-Meier statistics were used to estimate the probability that patients would continue in the study without having an exit event. RESULTS: Time to exit event was longer for patients on 900 mg/day (n = 72) or 1,800 mg/day (n = 74) of gabapentin than for patients receiving 300 mg/day (n = 72; p = 0.0395 and 0.0175, respectively). The most clinically relevant measure of retention on treatment (exit event plus adverse event withdrawal rate) was similar for carbamazepine (n = 74) and 1,800 mg/day gabapentin (54% versus 57%) but was lower (better) for 900 mg/day gabapentin (44%). No unexpected new adverse events emerged with gabapentin monotherapy. CONCLUSIONS:
|
Authors | D W Chadwick, H Anhut, M J Greiner, J Alexander, G H Murray, E A Garofalo, M W Pierce |
Journal | Neurology
(Neurology)
Vol. 51
Issue 5
Pg. 1282-8
(Nov 1998)
ISSN: 0028-3878 [Print] United States |
PMID | 9818846
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Acetates
- Amines
- Anticonvulsants
- Cyclohexanecarboxylic Acids
- Carbamazepine
- gamma-Aminobutyric Acid
- Gabapentin
|
Topics |
- Acetates
(adverse effects, therapeutic use)
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Amines
- Anticonvulsants
(adverse effects, therapeutic use)
- Carbamazepine
(adverse effects, therapeutic use)
- Child
- Cyclohexanecarboxylic Acids
- Dose-Response Relationship, Drug
- Double-Blind Method
- Epilepsies, Partial
(drug therapy)
- Female
- Gabapentin
- Humans
- Male
- Medical Records
- Middle Aged
- Seizures
(drug therapy)
- gamma-Aminobutyric Acid
|